CervoMed Inc.

CervoMed Inc.

CRVO·NASDAQ

$5.50

-0.36%
HealthcareBiotechnology

CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of drug treatments for neurodegenerative diseases. It develops neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, and brain stroke recovery. The company is based in Boston, Massachusetts.

At a Glance

Live Snapshot
Market Cap$50.89M
EPS-2.0200
P/E Ratio-1.16
Earnings Date03/16/2026

crvo

Total Current Assets

Last Annual Value

43.08M

3-Year CAGR

4%

5-Year CAGR

24%

10-Year CAGR

6%

CervoMed Inc.

CervoMed Inc. Competitors Analysis of Total Current Assets

CRVO · NASDAQ
CompanyTotal Current Assets
CAGR 3Y
CAGR 5Y
CAGR 10Y
CRVO logo
CervoMed Inc.
NASDAQ:CRVO
43.08M
62.9%2.6%39.0% 
8.89M
8.9%-22.9%N/A
123.84M
1.9%-18.6%1.2%
5.53M
91.3%77.6%N/A
ACET logo
Adicet Bio, Inc.
NASDAQ:ACET
160.93M
-0.3%-10.6%-7.5%
CLNN logo
Clene Inc.
NASDAQ:CLNN
8.98M
-38.6%-30.3%N/A
58.59M
-24.9%-18.3%N/A
18.75M
3.8%-17.4%31.4%
101.24M
72.3%41.0%N/A
115.23M
-17.8%-17.5%N/A
VXRT logo
Vaxart, Inc.
NASDAQ:VXRT
115.15M
36.2%-7.4%11.2%
CervoMed Inc.

CervoMed Inc. Fair Value Envelope

CRVO · NASDAQ

Our analysis suggests that CRVO has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $5.5, this represents a potential HIDDEN relative to our calculated worth for CervoMed Inc..

Intrinsic Value
Current Price: $5.5